A randomized trial in Nature Communications reported that the oral CDK7 inhibitor samuraciclib plus fulvestrant improved clinical benefit rates in women with advanced HR-positive, HER2-negative breast cancer previously treated with CDK4/6 inhibitors. The study supports a strategy of targeting transcriptional regulation through CDK7 in a population with limited options after first-line pathway resistance. For drug developers, the result reinforces a second-wave mechanism competition—moving beyond CDK4/6 blockade toward broader cell-cycle and transcriptional control. If confirmed in larger phase programs and additional endpoints, this regimen could become an important post-CDK4/6 option. The headline summary did not include hazard ratios or median outcomes, but the randomized design and phase context position it as a meaningful clinical pipeline update for oncology investors.